insulin degludec
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | TRESIBA | — | 2016-12-16 – 2022-07-01 | fda.gov ↗ |
| Approved | US (FDA) | TRESIBA | — | 2015-09-25 | fda.gov ↗ |
| Approved | EU (EMA) | Tresiba | — | 2013-01-20 | europa.eu ↗ |
Trials 101 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03400501 | Oct 2017 → Jun 2021 | type 1 diabetes mellitus | Yale University | Completed | No outcome recorded |
| Phase 138 trials | ||||||
| Phase 1 | NCT06449703 | May → Jun 2024 | — | Tonghua Dongbao Pharmaceutical Co.,Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT06556641 | Dec 2022 → Feb 2023 | — | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
| Phase 1 | NCT05576298 | Oct 2021 → Mar 2022 | type 2 diabetes mellitus | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04569994 | Sep 2020 → Jun 2021 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03726125 | Nov 2018 → Sep 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03292185 | Sep 2017 → Jan 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02536859 | Aug 2015 → Apr 2016 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01773798 | Jan → Aug 2013 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01704417 | Oct 2012 → Mar 2013 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01623375 | Jun → Aug 2012 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01590836 | Apr → Jun 2012 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01467414 | Oct → Dec 2011 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 1 | NCT01437592 | Sep → Nov 2011 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01193387 | Aug → Nov 2010 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01173926 | Jul → Nov 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01151072 | Jun → Oct 2010 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01135927 | Jun → Oct 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01154881 | Jun → Nov 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01114542 | May → Aug 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01076634 | Feb → Jul 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01043510 | Jan → Oct 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01030926 | Dec 2009 → May 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01006057 | Nov 2009 → May 2010 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01002768 | Oct 2009 → Mar 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00992537 | Oct 2009 → Jan 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00983021 | Sep → Dec 2009 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00964964 | Aug → Sep 2009 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00966368 | Aug → Oct 2009 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00964418 | Aug → Nov 2009 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00976326 | Aug 2009 → Mar 2010 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00961324 | Jul → Oct 2009 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01868568 | Apr → Aug 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01868529 | Jan → Jun 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01868555 | Dec 2007 → Feb 2008 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01865331 | Dec 2006 → Mar 2007 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01865305 | Sep 2006 → Feb 2007 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01865318 | Sep 2006 → Jan 2007 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01865292 | Aug → Nov 2006 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT04585776 | Oct 2020 → May 2021 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT03938740 | Mar → Dec 2019 | type 1 diabetes mellitus | Diasome Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00841087 | Jan → May 2009 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT00612040 | Jan → Jun 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT00611884 | Jan → Aug 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03387787 | Jan 2018 → Jan 2020 | type 2 diabetes mellitus | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 341 trials | ||||||
| Phase 3 | NCT05802862 | Jul 2023 → Aug 2024 | diabetes mellitus | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05767255 | Dec 2022 → Aug 2023 | type 2 diabetes mellitus | Hospital Universitario San Ignacio | Unknown | No outcome recorded |
| Phase 3 | NCT05641337 | Oct 2022 → Dec 2025 | cirrhosis of liver, diabetes mellitus | Huashan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04955834 | Jul 2021 → Dec 2025 | type 2 diabetes mellitus | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04795531 | Mar 2021 → Jun 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03862716 | Apr 2019 → Jun 2022 | type 2 diabetes mellitus | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT03377699 | Nov 2017 → Dec 2020 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03175120 | May 2017 → Mar 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03172494 | May 2017 → Jun 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03078478 | Mar 2017 → Feb 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02501161 | Jan 2016 → Oct 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02607306 | Nov 2015 → Dec 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02030600 | Jan 2014 → Dec 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02034513 | Jan 2014 → Jan 2016 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01959529 | Oct 2013 → Oct 2016 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01849289 | Jun 2013 → May 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01880736 | Jun 2013 → Apr 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01814137 | Mar 2013 → Mar 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01713530 | Feb 2013 → Jan 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01664247 | Oct 2012 → Dec 2013 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01676116 | Aug 2012 → Mar 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01570751 | Apr 2012 → Jan 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01569841 | Apr → Nov 2012 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01513473 | Jan 2012 → Jul 2013 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01392573 | Nov 2011 → Oct 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01388361 | Sep 2011 → Jul 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01364428 | Jun 2011 → Jan 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01336023 | May 2011 → May 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01326026 | Mar → Dec 2011 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01135992 | Jun → Nov 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01068665 | Mar → Nov 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01076647 | Mar → Dec 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01079234 | Mar → Nov 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01059799 | Feb → Dec 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01068678 | Feb → Nov 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01074268 | Feb → Dec 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01046110 | Jan → Nov 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01006291 | Nov 2009 → Sep 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00972283 | Sep 2009 → Oct 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00982228 | Sep 2009 → Nov 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00982644 | Sep 2009 → Dec 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT06925334 | May 2024 → Dec 2025 overdue | diabetes mellitus, noninsulin-dependent, 2 | Beijing Tsinghua Chang Gung Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07599891 | Sep 2023 → Mar 2025 | hyperglycemia | Max Healthcare Insititute Limited | Completed | No outcome recorded |
| Phase 4 | NCT05904743 | Jul 2023 → Mar 2024 | type 1 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 4 | NCT05243628 | Mar → Oct 2022 | type 1 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 4 | NCT04623086 | Feb 2020 → Sep 2022 | type 1 diabetes mellitus | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT03987191 | Jan → Oct 2020 | type 1 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT04027023 | Oct 2019 → Apr 2021 | type 2 diabetes mellitus | Sciema UG | Unknown | No outcome recorded |
| Phase 4 | NCT03668808 | Nov 2018 → Sep 2020 | type 1 diabetes mellitus | Sansum Diabetes Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03687827 | Oct 2018 → Dec 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT03838783 | May 2018 → Apr 2019 | type 1 diabetes mellitus | LMC Diabetes & Endocrinology Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT03328845 | Jan 2017 → Nov 2020 | type 1 diabetes mellitus | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | Completed | No outcome recorded |
| Phase 4 | NCT02192450 | Jan 2015 → Feb 2019 | hypoglycemia, type 1 diabetes mellitus | Nordsjaellands Hospital | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06056167 | May 2023 → May 2024 | diabetes mellitus, hyperglycemia | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT05417841 | Mar 2023 → Aug 2025 | type 2 diabetes mellitus | Beijing Hospital | Completed | No outcome recorded |
| — | NCT04190160 | Nov 2018 → Nov 2019 | type 2 diabetes mellitus | Stefano Rizza | Completed | No outcome recorded |
Also used as a comparator or background therapy in 56 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT07630233 Comparator | Jun → Oct 2026 expected | type 2 diabetes mellitus | The United Bio-Technology (Hengqin) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07376200 Comparator | Feb → Sep 2026 expected | — | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07032688 Background | Aug 2025 → Mar 2027 expected | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06685185 Comparator | Nov 2024 → Mar 2026 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06280703 Comparator | May 2024 → Sep 2026 expected | type 1 diabetes mellitus | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06288412 Background | Feb 2024 → Mar 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06132126 Comparator | Nov 2023 → Jun 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06553248 Comparator | Mar → Nov 2023 | type 2 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
| Phase 1 | NCT04276428 Comparator | Feb → Nov 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02964104 Comparator | Nov 2016 → Dec 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02148861 Comparator | May 2014 → Jun 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01319240 Comparator | Mar → May 2011 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01865279 Comparator | Dec 2005 → Apr 2006 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07018453 Comparator | Jul 2025 → Feb 2026 overdue | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06202079 Comparator | Aug 2023 → Jul 2024 | type 2 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
| Phase 2 | NCT04663282 Comparator | Feb 2021 → May 2022 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04450407 Comparator | Jul 2020 → Oct 2021 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT04450394 Comparator | Jul 2020 → Oct 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT03736785 Comparator | Nov 2018 → Feb 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 321 trials | ||||||
| Phase 3 | NCT07527078 Comparator | Apr 2026 overdue | type 2 diabetes mellitus | Gan & Lee Pharmaceuticals. | Recruiting | No outcome recorded |
| Phase 3 | NCT06767748 Comparator | Feb 2025 → Feb 2026 overdue | type 2 diabetes mellitus | Gan & Lee Pharmaceuticals. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05463744 Comparator | Aug 2022 → May 2024 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05362058 Comparator | Jun 2022 → Apr 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05275400 Comparator | Mar 2022 → May 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04974528 Background | Sep 2021 → Oct 2024 | type 1 diabetes mellitus, type 2 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04848480 Comparator | Apr 2021 → Apr 2022 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04770532 Comparator | Mar 2021 → Jan 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04760626 Comparator | Mar 2021 → Aug 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04588259 Background | Oct 2020 → Jul 2022 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03952130 Background | May 2019 → Jan 2022 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03952143 Background | May 2019 → Jan 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03740919 Comparator | Apr 2019 → Jul 2021 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03882970 Comparator | Apr 2019 → Dec 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03737240 Comparator | Jan 2019 → Jul 2022 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 3 | NCT03268005 Background | Sep 2017 → Jan 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03214367 Background | Jul 2017 → Sep 2018 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03214380 Background | Jul 2017 → Aug 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02911948 Comparator | Sep 2016 → Nov 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02670915 Background | May 2016 → Feb 2018 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02500706 Background | May 2016 → Jul 2017 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT07173712 Comparator | Mar 2026 → Jun 2027 expected | type 2 diabetes mellitus | Yanbing Li | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07112339 Comparator | Aug 2025 → Aug 2026 overdue | type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 4 | NCT05552859 Comparator | Dec 2022 → Jul 2023 | impaired renal function disease, type 2 diabetes mellitus | Sanofi | Terminated | No outcome recorded |
| Phase 4 | NCT05218915 Background | Jan 2022 → Oct 2024 | diabetes mellitus, diabetic kidney disease | Elaine Chow | Completed | No outcome recorded |
| Phase 4 | NCT04538352 Background | Jan 2021 → Mar 2023 | type 2 diabetes mellitus | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT04075513 Comparator | Oct 2019 → Sep 2021 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT04692415 Comparator | Dec 2018 → Jun 2019 | type 2 diabetes mellitus | University of Split, School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03349840 Comparator | Jan → Aug 2018 | type 2 diabetes mellitus | Weill Cornell Medical College in Qatar | Terminated | No outcome recorded |
| Phase 4 | NCT03244241 Comparator | Apr 2017 → Apr 2018 | type 2 diabetes mellitus | Merete Bechmann Christensen | Unknown | No outcome recorded |
| Phase 4 | NCT02738151 Comparator | May 2016 → Aug 2017 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02967211 Comparator | Dec 2015 → Oct 2017 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02967224 Comparator | Nov 2015 → Oct 2017 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02680457 Comparator | Nov 2013 → Jul 2015 | type 2 diabetes mellitus | University of Guadalajara | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06178874 Comparator | Dec 2023 → May 2024 | glucose metabolism disease | Ain Shams University | Completed | No outcome recorded |
| — | NCT04965051 Comparator | Aug 2021 → Dec 2023 | type 1 diabetes mellitus | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT02846233 Comparator | Aug 2016 → Dec 2018 | type 2 diabetes mellitus | University of California, San Francisco | Completed | No outcome recorded |
Press releases naming this drug 66 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-07-29 | Novo Nordisk A/S | Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3 novonordisk.com ↗ |
| 2022-04-28 | Novo Nordisk A/S | Once-weekly insulin icodec demonstrates superior reduction in HbA1c vs insulin degludec in people with type 2 diabetes in ONWARDS 2 phase 3a trial novonordisk.com ↗ |
| 2018-03-26 | Novo Nordisk A/S | FDA godkender opdatering af indlægssedlen for Tresiba® med data for forekomsten af hjerte-kar-sygdom og alvorlig hypoglykæmi novonordisk.com ↗ |
| 2018-03-26 | Novo Nordisk A/S | FDA approves inclusion of data on cardiovascular outcomes and severe hypoglycaemia in the Tresiba® label novonordisk.com ↗ |
| 2017-09-29 | Novo Nordisk A/S | CHMP støtter opdatering af indlægssedlen for Tresiba® i EU - ny indlægsseddel afspejler signifikant reduktion i risikoen for alvorlig hypoglykæmi novonordisk.com ↗ |
| 2017-09-29 | Novo Nordisk A/S | CHMP endorses Tresiba® label update in the EU - new label reflects significant reduction in the risk of severe hypoglycaemia novonordisk.com ↗ |
| 2017-06-14 | Novo Nordisk A/S | Novo Nordisk submits application in the EU for including data from the DEVOTE trial in the Tresiba® label novonordisk.com ↗ |
| 2017-06-14 | Novo Nordisk A/S | Novo Nordisk indsender ansøgning i EU om inkludering af data fra DEVOTE-studiet i indlægssedlen for Tresiba® novonordisk.com ↗ |
| 2017-05-27 | Novo Nordisk A/S | Novo Nordisk submits application in the US for including data from the DEVOTE trial in the Tresiba® label novonordisk.com ↗ |
| 2017-05-27 | Novo Nordisk A/S | Novo Nordisk indsender ansøgning i USA om inkludering af data fra DEVOTE-studiet i indlægssedlen for Tresiba® novonordisk.com ↗ |
| 2017-03-24 | Novo Nordisk A/S | CHMP provides positive opinion for EU label update for Novo Nordisk's Tresiba® based on data from SWITCH trials novonordisk.com ↗ |
| 2017-03-24 | Novo Nordisk A/S | CHMP afgiver positiv udtalelse om opdatering af indlægssedlen for Novo Nordisks Tresiba® i EU baseret på data fra SWITCH-studierne novonordisk.com ↗ |
| 2016-11-29 | Novo Nordisk A/S | Novo Nordisk A/S: Tresiba® demonstrates a safe cardiovascular profile and reduces the risk of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial novonordisk.com ↗ |
| 2016-11-29 | Novo Nordisk A/S | Novo Nordisk A/S: Tresiba® viser en sikker kardiovaskulær profil og reducerer risikoen for alvorlig hypoglykæmi sammenlignet med insulin glargin U100 i DEVOTE-studiet novonordisk.com ↗ |
| 2016-11-10 | Novo Nordisk A/S | Novo Nordisk submits application in the EU for including data from the two SWITCH trials in Tresiba® label novonordisk.com ↗ |
| 2016-11-10 | Novo Nordisk A/S | Novo Nordisk indsender ansøgning i EU om inkludering af data fra de to SWITCH-studier i indlægssedlen for Tresiba® novonordisk.com ↗ |
| 2016-09-23 | Novo Nordisk A/S | Novo Nordisk indsender ansøgning i USA om inkludering af data fra de to SWITCH-studier i indlægssedlen for Tresiba® novonordisk.com ↗ |
| 2016-09-23 | Novo Nordisk A/S | Novo Nordisk submits application in the US for including data from the two SWITCH trials in Tresiba® label novonordisk.com ↗ |
| 2016-05-20 | Novo Nordisk A/S | FDA offentliggør briefingmateriale forud for møde i rådgivende komite om IDegLira, en kombination af insulin degludec og liraglutid novonordisk.com ↗ |
| 2016-05-20 | Novo Nordisk A/S | FDA posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination product of insulin degludec and liraglutide novonordisk.com ↗ |
| 2016-02-23 | Novo Nordisk A/S | Tresiba® viser signifikant lavere forekomst af hypoglykæmi end insulin glargin U100 i blindet fase 3b-studie i mennesker med type 1-diabetes novonordisk.com ↗ |
| 2016-02-23 | Novo Nordisk A/S | Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine U100 in blinded phase 3b trial in people with type 1 diabetes novonordisk.com ↗ |
| 2016-01-29 | Novo Nordisk A/S | Tresiba® viser signifikant lavere forekomst af hypoglykæmi end insulin glargin i blindet fase 3b-studie i mennesker med type 2-diabetes novonordisk.com ↗ |
| 2016-01-29 | Novo Nordisk A/S | Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine in blinded phase 3b trial in people with type 2 diabetes novonordisk.com ↗ |
| 2015-09-25 | Novo Nordisk A/S | Novo Nordisk får FDA-godkendelse for Tresiba® og Ryzodeg® 70/30 i USA novonordisk.com ↗ |
| 2015-09-25 | Novo Nordisk A/S | Novo Nordisk receives US FDA approval for Tresiba® and Ryzodeg® 70/30 novonordisk.com ↗ |
| 2015-04-07 | Novo Nordisk A/S | Novo Nordisk A/S: Amerikanske FDA accepterer at behandle genindsendelserne af Tresiba® og Ryzodeg® novonordisk.com ↗ |
| 2015-04-07 | Novo Nordisk A/S | US FDA accepts Tresiba® and Ryzodeg® resubmissions for review novonordisk.com ↗ |
| 2015-03-26 | Novo Nordisk A/S | Novo Nordisk har besluttet at genindsende registreringsansøgningerne for Tresiba® og Ryzodeg® i USA novonordisk.com ↗ |
| 2015-03-26 | Novo Nordisk A/S | Novo Nordisk har besluttet at genindsende registreringsansøgningerne for Tresiba® og Ryzodeg® i USA novonordisk.com ↗ |
| 2015-03-26 | Novo Nordisk A/S | Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US novonordisk.com ↗ |
| 2015-03-26 | Novo Nordisk A/S | Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US novonordisk.com ↗ |
| 2013-02-10 | Novo Nordisk A/S | Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg® novonordisk.com ↗ |
| 2013-02-10 | Novo Nordisk A/S | Novo Nordisk modtager Complete Response Letter i USA vedrørende Tresiba® og Ryzodeg® novonordisk.com ↗ |
| 2013-01-21 | Novo Nordisk A/S | Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) får markedsføringstilladelse i Europa novonordisk.com ↗ |
| 2013-01-21 | Novo Nordisk A/S | Tresiba® and Ryzodeg® receive marketing authorisations in Europe novonordisk.com ↗ |
| 2012-12-25 | Novo Nordisk A/S | Ryzodeg® (insulin degludec/insulin aspart) approved in Japan novonordisk.com ↗ |
| 2012-12-25 | Novo Nordisk A/S | Ryzodeg® (insulin degludec/insulin aspart) godkendt i Japan novonordisk.com ↗ |
| 2012-12-03 | Novo Nordisk A/S | Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan novonordisk.com ↗ |
| 2012-12-03 | Novo Nordisk A/S | Ryzodeg® (insulin degludec/insulin aspart) passerer evaluering i japansk medicinkomite novonordisk.com ↗ |
| 2012-11-08 | Novo Nordisk A/S | Positiv afstemning i FDA's rådgivende komite vedrørende godkendelse af insulin degludec og insulin degludec/ insulin aspart novonordisk.com ↗ |
| 2012-11-08 | Novo Nordisk A/S | Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval from FDA Advisory Committee novonordisk.com ↗ |
| 2012-11-06 | Novo Nordisk A/S | FDA offentliggør briefingmateriale forud for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-11-06 | Novo Nordisk A/S | FDA posts briefing materials prior to Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-10-25 | Novo Nordisk A/S | FDA offentliggør fokus for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-10-25 | Novo Nordisk A/S | FDA discloses focus of Advisory Committee meeting on insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-10-19 | Novo Nordisk A/S | Novo Nordisk modtager positive udtalelser om Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) fra de europæiske registreringsmyndigheder novonordisk.com ↗ |
| 2012-10-19 | Novo Nordisk A/S | Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities novonordisk.com ↗ |
| 2012-10-18 | Novo Nordisk A/S | Japan's Pharmaceuticals and Medical Devices Agency publishes assessment report of Tresiba® novonordisk.com ↗ |
| 2012-10-18 | Novo Nordisk A/S | Japansk lægemiddelagentur offentliggør evalueringsrapport om Tresiba® novonordisk.com ↗ |
| 2012-09-28 | Novo Nordisk A/S | Novo Nordisk A/S: Tresiba® (insulin degludec) approved in Japan novonordisk.com ↗ |
| 2012-09-28 | Novo Nordisk A/S | Novo Nordisk A/S: Tresiba® (insulin degludec) godkendt i Japan novonordisk.com ↗ |
| 2012-08-31 | Novo Nordisk A/S | Novo Nordisk A/S : Insulin degludec passerer evalueringen i japansk medicinkomite novonordisk.com ↗ |
| 2012-08-31 | Novo Nordisk A/S | Novo Nordisk A/S : Insulin degludec passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan novonordisk.com ↗ |
| 2012-07-18 | Novo Nordisk A/S | Novo Nordisk A/S: FDA berammer møde i rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-07-18 | Novo Nordisk A/S | Novo Nordisk A/S: FDA schedules Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-06-08 | Novo Nordisk A/S | Novo Nordisk A/S: FDA forlænger registreringssprocessen for insulin degludec og insulin degludec/insulin aspart med tre måneder novonordisk.com ↗ |
| 2012-06-08 | Novo Nordisk A/S | Novo Nordisk A/S: FDA extends regulatory review period for insulin degludec and insulin degludec/insulin aspart by three months novonordisk.com ↗ |
| 2011-12-22 | Novo Nordisk A/S | Novo Nordisk indsender registreringsansøgning for den ultralangtidsvirkende insulinanalog, Degludec, i Japan novonordisk.com ↗ |
| 2011-12-22 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of the ultra-long-acting insulin Degludec in Japan novonordisk.com ↗ |
| 2011-09-29 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in the US novonordisk.com ↗ |
| 2011-09-29 | Novo Nordisk A/S | Novo Nordisk indsender registreringsansøgning for de ultralangtidsvirkende insulinpræparater Degludec og DegludecPlus i USA novonordisk.com ↗ |
| 2011-09-26 | Novo Nordisk A/S | Novo Nordisk indsender registreringsansøgning for de ultralangtidsvirkende insulinpræparater Degludec og DegludecPlus i Europa novonordisk.com ↗ |
| 2011-09-26 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in Europe novonordisk.com ↗ |
| 2010-12-22 | Novo Nordisk A/S | Degludec giver væsentligt nedsat risiko for natlig hypoglykæmi sammenlignet med insulin glargin i to langtidsstudier novonordisk.com ↗ |
| 2010-12-22 | Novo Nordisk A/S | Degludec significantly reduces risk of hypoglycaemia during the night compared to insulin glargine in two long-term studies novonordisk.com ↗ |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 195 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | insulin degludec | “The combination of insulin degludec (100 units/mL) and liraglutide (3.6 mg/mL), termed IDegLira, was approved in 2014 for the treatment of type 2 diabetes inadequately...” NCT04190160 ↗152“The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for...” NCT07112339 ↗ “The study aims to compare insulin glargine, a long-acting basal insulin with approximately 24-hour duration, and insulin degludec, an ultra-long-acting basal insulin with about...” NCT07599891 ↗ “To assess the effectiveness of using insulin degludec as basal insulin in conjunction with subcutaneous regular insulin sliding scale (ISS) in the glycemic control in...” NCT06056167 ↗ “There is an ongoing discussion about possible differences between insulin degludec (IDeg-100) and glargine U300 (IGlar-300).” PMID 35802405 ↗ Jul 2022 “The participants received an abdominal subcutaneous injection of Insulin Degludec in the morning of Day 1.” NCT07376200 ↗ “Individualized basal insulin (insulin degludec, insulin glargine or insulin detemir) for each patient.” NCT04974528 ↗ “Insulin degludec is associated with a lower risk of nocturnal hypoglycemia in T1D.” PMID 35467938 ↗ Jun 2022 “insulin degludec (5 to 15 U at bedtime)” NCT04027023 ↗ “Drug: insulin degludec” NCT00612040 ↗ |
| Known as | degludec | “ABBREVIATIONS: A1C = hemoglobin A1C; AE = adverse event; CI = confidence interval; Degludec = insulin degludec; EOT = end of trial; ETD = estimated treatment difference; FPG =...” PMID 30383495 ↗ Nov 201812“The aim of this trial is to compare efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar), as add-on to subject's ongoing treatment with...” NCT01068665 ↗ “INTRODUCTION: DUAL II Japan (NCT02911948) was a 26-week, phase 3a randomized, treat-to-target trial which compared the efficacy and safety of IDegLira with degludec in 210...” PMID 31760599 ↗ Nov 2019 “METHODS: This phase 3a, treat-to-target multicenter trial randomized participants (glycated hemoglobin [HbA1c] 53.0-85.8 mmol/mol; previous metformin ± another OAD) 2:1:1 to...” PMID 35762390 ↗ Jun 2022 “The aim of the current study was to assess the efficacy and safety of once-weekly efsitora compared with daily insulin degludec (degludec) in adults with type 2 diabetes using...” PMID 40562047 ↗ Jun 2025 “comparing the efficacy and safety of once-weekly insulin icodec (icodec) versus once-daily insulin degludec (degludec) in insulin-naive participants with type 2 diabetes (T2D).” PMID 40016570 ↗ Feb 2025 “This phase 3 study aimed to assess the efficacy and safety of efsitora compared with insulin degludec (degludec) in adults with type 1 diabetes.” PMID 39270686 ↗ Sep 2024 “The aim of the trial is to confirm the efficacy of IDeg (insulin degludec) versus IGlar (insulin glargine) in controlling glycaemia.” NCT01570751 ↗ “once-daily insulin degludec (degludec) in basal insulin-treated type 2 diabetes” PMID 37148899 ↗ May 2023 “once-daily insulin degludec (degludec) in adults with type 1 diabetes” PMID 40742780 ↗ Jul 2025 “insulin degludec 200 units/mL (degludec)” PMID 32306247 ↗ Apr 2020 “insulin degludec (degludec)” PMID 30362250 ↗ Nov 2018 “Insulin degludec (degludec)” PMID 36623517 ↗ Jan 2023 |
| Known as | Degludec insulin | “Drug: Degludec insulin” NCT07376200 ↗ |
| Known as | IDeg | “The aim of this trial is to compare efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar), as add-on to subject's ongoing treatment with...” NCT01068665 ↗38“The aim of this clinical trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2 diabetes...” NCT01068678 ↗ “The purpose of the present study was to provide clinical data on the efficacy and safety of insulin degludec (IDeg) 200 U/mL compared with IDeg 100 U/mL in patients with type 2...” PMID 24518180 ↗ Aug 2014 “The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or maximum...” NCT01664247 ↗ “This trial assessed the efficacy and safety of the possibility of varying the daily injection time of once-daily, long-acting basal insulin degludec (IDeg) in Japanese patients...” PMID 27182031 ↗ Apr 2016 “Insulin degludec (IDeg) is a new-generation, ultra-long-acting basal insulin that forms soluble multihexamers upon subcutaneous injection, resulting in a depot from which IDeg...” PMID 22726241 ↗ Jul 2012 “This trial is conducted in Europe. The aim of the trial is to compare the effect of exercise on blood glucose in subjects with type 1 diabetes, who are treated with either...” NCT01704417 ↗ “The objective of this trial was to confirm the efficacy and compare the safety of insulin degludec (IDeg) with insulin glargine (IGlar) in a multinational setting with two...” PMID 27098525 ↗ Jun 2016 “The efficacy and safety of insulin degludec (IDeg) was compared with insulin detemir (IDet), both administered once daily (OD) as basal treatment in participants with type 1...” PMID 24702700 ↗ May 2014 “This trial is conducted in Europe. The aim of this clinical trial is to investigate if two identical formulations of NN1250 (insulin degludec, IDeg) have the same level of drug...” NCT01193387 ↗ “Subjects completing 104 weeks (52-week main trial BEGIN ONCE-LONG + 52-week extension) on insulin degludec (IDeg) OD + metformin with HbA1c ≥ 7.0% (≥53 mmol/mol) were...” PMID 24443830 ↗ Feb 2014 “AIM: To compare day-to-day and within-day variability in glucose-lowering effect between insulin degludec (IDeg) and insulin glargine 300 U/mL (IGlar-U300) in type 1 diabetes.” PMID 28295934 ↗ Apr 2017 “The aim of the trial is to investigate the pharmacodynamic properties (effect) by comparing two NN1250 (insulin degludec, IDeg) formulations in subjects with type 1 diabetes.” NCT01076634 ↗ “insulin degludec (IDeg) and insulin aspart (IAsp)--administered as a co-formulation (IDegAsp) or as a basal-bolus regimen (IDeg and IAsp in separate injections).” PMID 26592732 ↗ Jan 2016 “The present study aimed to evaluate the pharmacokinetic and pharmacodynamic properties of insulin degludec (IDeg) in Japanese patients with type 1 diabetes.” PMID 27042281 ↗ Aug 2015 “NN5401 (insulin degludec/insulin aspart, IDegAsp) with NN1250 (insulin degludec, IDeg) and insulin aspart (IAsp) in subjects with type 1 diabetes mellitus.” NCT01173926 ↗ “Insulin degludec (IDeg) is a basal insulin that forms soluble multihexamers after subcutaneous injection, resulting in an ultra-long action profile.” PMID 21270174 ↗ Jan 2011 “Insulin degludec (Des(B30)LysB29(γ-Glu Nε-hexadecandioyl) human insulin; IDeg) is a new basal insulin with an ultra-long flat action profile.” PMID 24057153 ↗ Sep 2013 “The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients with type 2 diabetes.” NCT01006291 ↗ “The aim of the trial is to confirm the efficacy of IDeg (insulin degludec) versus IGlar (insulin glargine) in controlling glycaemia.” NCT01570751 ↗ “Insulin degludec (IDeg) has an ultra-long and stable glucose-lowering effect, with low day-to-day variability.” PMID 23130654 ↗ Dec 2012 “insulin degludec/liraglutide (IDegLira) is a novel combination of insulin degludec (IDeg) and liraglutide.” PMID 25114296 ↗ Aug 2014 “by switching to a basal-bolus regimen of insulin degludec (IDeg) plus IAsp taken three times a day (TID)” PMID 27853981 ↗ Nov 2016 “Insulin degludec (IDeg) is an ultra-long-acting basal insulin with a consistent action profile of >42 h.” PMID 24843715 ↗ Jun 2013 “Twenty-two subjects received once-daily insulin degludec (IDeg) (0.42 U/kg) for five consecutive days” PMID 24888255 ↗ Jun 2014 “NN1250 (insulin degludec (IDeg)) once daily in insulin naïve subjects with type 2 diabetes mellitus” NCT01326026 ↗ “Insulin degludec (IDeg) once-daily was compared with insulin detemir (IDet) once- or twice-daily” PMID 25683037 ↗ Feb 2015 “Insulin degludec (IDeg) is a new-generation basal insulin with an ultra-long duration of action.” PMID 22594461 ↗ Jun 2012 “Insulin degludec (IDeg) is a basal insulin with an ultra-long pharmacokinetic profile in adults” PMID 24467565 ↗ Feb 2014 “the basal insulin insulin degludec (IDeg) and liraglutide, a glucagon-like peptide-1 analog.” PMID 25998481 ↗ Jul 2015 “Insulin degludec (IDeg), a new basal insulin with an ultra-long duration of action” PMID 23577643 ↗ May 2013 “insulin degludec (IDeg), a basal insulin with an ultra-long duration of action” PMID 24263619 ↗ Jan 2014 “NN1250 (insulin degludec (IDeg)), a soluble insulin basal analogue (SIBA)” NCT01076647 ↗ “insulin degludec (IDeg), a new-generation once-daily basal insulin” PMID 25124362 ↗ Sep 2014 “NN1250 (insulin degludec, IDeg) in subjects with type 2 diabetes” NCT01043510 ↗ “Insulin degludec (IDeg) is a new basal insulin.” PMID 26232910 ↗ Jun 2015 “NN1250 (insulin degludec (IDeg))” NCT00992537 ↗ “NN1250 (insulin degludec (IDeg))” NCT00972283 ↗ “insulin degludec (IDeg)” NCT01959529 ↗ |
| Known as | IDeg-100 | “OBJECTIVE: To compare insulin glargine 300 units/mL (Gla-300) versus insulin degludec 100 units/mL (IDeg-100) in this first head-to-head randomized controlled trial.” PMID 30104294 ↗ Aug 20182“To date, only limited data comparing the second-generation insulins glargine 300 U/mL (Gla-300) and degludec 100 U/mL (IDeg-100) in people with T1D are available” PMID 32100192 ↗ Feb 2020 “There is an ongoing discussion about possible differences between insulin degludec (IDeg-100) and glargine U300 (IGlar-300).” PMID 35802405 ↗ Jul 2022 |
| Known as | insulin 454 | “The aim of this trial was to compare the pharmacodynamic (the effect of the investigated drug on the body) response of insulin degludec (insulin 454) with insulin glargine at...” NCT01868529 ↗8“insulin degludec (insulin 454), an explorative formulation, not similar to the proposed commercial formulation, with insulin glargine in subjects with type 1 and type 2 diabetes.” NCT01865292 ↗ “The aim of this clinical trial was to evaluate the blood glucose-lowering effect of NN1250 (insulin degludec/insulin 454) in subjects with type 2 diabetes.” NCT01154881 ↗ “The aim of this clinical trial was to evaluate if the NN1250 (insulin degludec/insulin 454) concentration-time curve is altered” NCT01006057 ↗ “insulin degludec (insulin 454), an explorative formulation” NCT01865279 ↗ “two insulin degludec (insulin 454) preparations” NCT01868555 ↗ “insulin degludec (insulin 454)” NCT01868568 ↗ “insulin degludec (insulin 454)” NCT01865331 ↗ “insulin degludec (insulin 454)” NCT01865305 ↗ |
| Known as | insulin degludec/insulin aspart 15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01773798 ↗ |
| Known as | insulin degludec/insulin aspart 30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01865305 ↗ |
| Known as | insulin degludec/insulin aspart 40 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01865305 ↗ |
| Known as | insulin degludec/insulin aspart 45 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01868555 ↗ |
| Known as | insulin degludec/insulin aspart 50 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01865305 ↗ |
| Known as | NN1250 | “The aim of this trial is to compare efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar), as add-on to subject's ongoing treatment with...” NCT01068665 ↗26“The aim of this clinical trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2 diabetes...” NCT01068678 ↗ “This trial is conducted in Africa, Asia and North America. The aim of this trial is to compare two insulin degludec (NN1250, SIBA) formulations with each other and with insulin...” NCT00611884 ↗ “The aim of this clinical trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) properties of NN1250 (insulin degludec) in Japanese...” NCT01467414 ↗ “This trial is conducted in Europe. The aim of this clinical trial is to investigate if two identical formulations of NN1250 (insulin degludec, IDeg) have the same level of drug...” NCT01193387 ↗ “This trial was conducted in Europe. The aim of this clinical trial was to evaluate the effect on the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with...” NCT01114542 ↗ “The aim of the trial is to investigate the pharmacodynamic properties (effect) by comparing two NN1250 (insulin degludec, IDeg) formulations in subjects with type 1 diabetes.” NCT01076634 ↗ “The aim of this clinical trial is to evaluate the hypoglycaemic response (the response to low blood sugar) to NN1250 (insulin degludec) in subjects with type 1 diabetes.” NCT01002768 ↗ “The aim of this clinical trial was to evaluate the blood glucose-lowering effect of NN1250 (insulin degludec/insulin 454) in subjects with type 2 diabetes.” NCT01154881 ↗ “The aim of this clinical trial was to compare the exposure and effect of NN1250 (insulin degludec) after different routes of injection in healthy subjects.” NCT01151072 ↗ “NN5401 (insulin degludec/insulin aspart, IDegAsp) with NN1250 (insulin degludec, IDeg) and insulin aspart (IAsp) in subjects with type 1 diabetes mellitus.” NCT01173926 ↗ “The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients with type 2 diabetes.” NCT01006291 ↗ “during two different treatments with NN1250 (insulin degludec), a soluble insulin basal analogue (SIBA) in subjects with type 1 diabetes.” NCT00964964 ↗ “The aim of this clinical trial was to evaluate if the NN1250 (insulin degludec/insulin 454) concentration-time curve is altered” NCT01006057 ↗ “The aim of this trial is to investigate the efficacy and safety of NN1250 (insulin degludec) in subjects with type 1 diabetes.” NCT01079234 ↗ “NN1250 (insulin degludec (IDeg)) once daily in insulin naïve subjects with type 2 diabetes mellitus” NCT01326026 ↗ “NN1250 (insulin degludec, soluble insulin basal analogue (SIBA)) plus insulin aspart” NCT00982228 ↗ “NN1250 (insulin degludec) injected s.c. (under the skin) once daily for 6 days” NCT01135927 ↗ “NN1250 (insulin degludec (IDeg)), a soluble insulin basal analogue (SIBA)” NCT01076647 ↗ “The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime” NCT00841087 ↗ “NN1250 (insulin degludec, IDeg) in subjects with type 2 diabetes” NCT01043510 ↗ “two formulations of NN1250 (insulin degludec)” NCT00966368 ↗ “NN1250 (insulin degludec (IDeg))” NCT00992537 ↗ “NN1250 (insulin degludec (IDeg))” NCT00972283 ↗ “NN1250 (insulin degludec)” NCT01437592 ↗ “NN1250 (insulin degludec)” NCT00964418 ↗ “NN1250 (insulin degludec)” NCT01046110 ↗ |
| Known as | RD15003 | “Insulin degludec injection, RD15003” NCT05576298 ↗ |
| Known as | SIBA | “This trial is conducted in Africa, Asia and North America. The aim of this trial is to compare two insulin degludec (NN1250, SIBA) formulations with each other and with insulin...” NCT00611884 ↗1“to insulin degludec (NN1250, SIBA) on a basal-bolus regimen” NCT00841087 ↗ |
| Known as | Tresiba | “Participants will first receive insulin decludec (Tresiba®, a long-acting insulin taken once daily) for atleast one week.” NCT06288412 ↗7“Insulin degludec injection（Tresiba®）subcutaneous administration once daily for 26 weeks” NCT04955834 ↗ “Basal insulin (NPH, Lantus, Levimir, Toujeo or Tresiba)” NCT02846233 ↗ “Levemir/Lantus/Tresiba plus NovoLog/Humalog/Apidra” NCT04965051 ↗ “Insulin Degludec Injection (Tresiba®)” NCT07527078 ↗ “Insulin Degludec 100 UNT/ML [Tresiba]” NCT03244241 ↗ “Insulin degludec, Tresiba” NCT05576298 ↗ |
| Modality | Protein / enzyme biologic | “Insulin degludec (IDeg) is a basal insulin that forms soluble multihexamers after subcutaneous injection, resulting in an ultra-long action profile.” PMID 21270174 ↗ Jan 2011 |
| Route | Subcutaneous | “Insulin degludec is a new basal insulin that forms soluble multihexamer assemblies after subcutaneous injection, resulting in an ultra-long action profile.” PMID 21396703 ↗ Mar 2011 |